Skip to main content

Levothyroxine / liothyronine Pregnancy and Breastfeeding Warnings

Brand names: Adthyza

Levothyroxine / liothyronine Pregnancy Warnings

Use is considered acceptable.

US FDA pregnancy category: A

Animal studies have not been reported. Thyroid hormones do not readily cross the placenta. Clinical experience to date does not indicate any adverse effects on the fetus when thyroid hormones are administered to pregnant women. There are no controlled data in human pregnancy.

US FDA pregnancy category A: Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).

See references

Levothyroxine / liothyronine Breastfeeding Warnings

Caution is recommended.

Excreted into human milk: Yes

Comments:
-This drug is a mixture of levothyroxine (T4) and liothyronine (T3) which are normal components of human milk.
-Limited data on exogenous replacement doses of T4 show no adverse effects on nursing infants.
-Dose requirements may be increased in the postpartum period compared to pre-pregnancy requirements in women with Hashimoto's thyroiditis.

See references

References for pregnancy information

  1. (2001) "Product Information. Thyrolar (liotrix)." Forest Pharmaceuticals

References for breastfeeding information

  1. (2001) "Product Information. Thyrolar (liotrix)." Forest Pharmaceuticals
  2. United States National Library of Medicine (2013) Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer